Commentary/Editorials

Mac Cheever (1944–2021): a tribute to a life of achievement and service
Philip D Greenberg, Mary L Disis, Kim A Margolin, Lynn M Matrisian, Paul M Sondel

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e004433; DOI: 10.1136/jitc-2021-004433
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study
Ryan Sun, Zachary McCaw, Lu Tian, Hajime Uno, Fangxin Hong, Dae Hyun Kim, Lee-Jen Wei

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003323; DOI: 10.1136/jitc-2021-003323
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
David Hsiehchen, Magdalena Espinoza, Cristina Valero, Chul Ahn, Luc G T Morris

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003683; DOI: 10.1136/jitc-2021-003683
PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003431; DOI: 10.1136/jitc-2021-003431
Letter to the editor from Pant et al
Shubham Pant, Justin T Moyers, Aung Naing

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003991; DOI: 10.1136/jitc-2021-003991
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
Yi Que, Yang Hu, Dongchun Hong, Yizhuo Zhang

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002920; DOI: 10.1136/jitc-2021-002920
Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
Paolo Bossi, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini, Marco Merlano

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003154; DOI: 10.1136/jitc-2021-003154
Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?
Gintaras Zaleskis, Vita Pasukoniene, Dainius Characiejus, Vincas Urbonas

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003191; DOI: 10.1136/jitc-2021-003191
Author response to Cunha et al
Rivka R Colen, Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey, Priyadarshini Mamindla, Pascal O Zinn, Chaan Ng, Raghu Vikram, Spyridon Bakas, Christine B Peterson, Jordi Rodon Ahnert, Vivek Subbiah, Daniel D Karp, Bettzy Stephen, Joud Hajjar, Aung Naing

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003299; DOI: 10.1136/jitc-2021-003299
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Mateus Trinconi Cunha, Vinicius Jardim Carvalho, Rafael Maffei Loureiro, Carlos Eduardo Brantis-de-Carvalho, Murilo Bicudo Cintra, Gilberto de Castro Junior

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003044; DOI: 10.1136/jitc-2021-003044

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages